Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

You may be eligible if

• Adults with previously treated recurrent CLL who have measurable lymphadenopathy
• Require therapy for CLL
• Have experienced CLL progression \< 24 months since the completion of the last prior therapy
• Have disease that is not refractory to ofatumumab